M1 Medulloblastoma

High risk at any age

Robert P. Sanders, Arzu Onar, James M. Boyett, Alberto Broniscer, E. Brannon Morris, Ibrahim Qaddoumi, Gregory T. Armstrong, Frederick A. Boop, Robert A. Sanford, Larry E. Kun, Thomas E. Merchant, Amar Gajjar

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defin ed. Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. Results: 55 patients were <3 years old and 230 patients were >3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). Conclusions : Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.

Original languageEnglish (US)
Pages (from-to)351-355
Number of pages5
JournalJournal of Neuro-Oncology
Volume90
Issue number3
DOIs
StatePublished - Aug 18 2008

Fingerprint

Medulloblastoma
Family Physicians
Cell Biology
Radiotherapy
Survival
Therapeutics
Neoplasms

Keywords

  • Cytology
  • Infant
  • Medulloblastoma
  • Metastatic
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Sanders, R. P., Onar, A., Boyett, J. M., Broniscer, A., Morris, E. B., Qaddoumi, I., ... Gajjar, A. (2008). M1 Medulloblastoma: High risk at any age. Journal of Neuro-Oncology, 90(3), 351-355. https://doi.org/10.1007/s11060-008-9671-9

M1 Medulloblastoma : High risk at any age. / Sanders, Robert P.; Onar, Arzu; Boyett, James M.; Broniscer, Alberto; Morris, E. Brannon; Qaddoumi, Ibrahim; Armstrong, Gregory T.; Boop, Frederick A.; Sanford, Robert A.; Kun, Larry E.; Merchant, Thomas E.; Gajjar, Amar.

In: Journal of Neuro-Oncology, Vol. 90, No. 3, 18.08.2008, p. 351-355.

Research output: Contribution to journalArticle

Sanders, RP, Onar, A, Boyett, JM, Broniscer, A, Morris, EB, Qaddoumi, I, Armstrong, GT, Boop, FA, Sanford, RA, Kun, LE, Merchant, TE & Gajjar, A 2008, 'M1 Medulloblastoma: High risk at any age', Journal of Neuro-Oncology, vol. 90, no. 3, pp. 351-355. https://doi.org/10.1007/s11060-008-9671-9
Sanders RP, Onar A, Boyett JM, Broniscer A, Morris EB, Qaddoumi I et al. M1 Medulloblastoma: High risk at any age. Journal of Neuro-Oncology. 2008 Aug 18;90(3):351-355. https://doi.org/10.1007/s11060-008-9671-9
Sanders, Robert P. ; Onar, Arzu ; Boyett, James M. ; Broniscer, Alberto ; Morris, E. Brannon ; Qaddoumi, Ibrahim ; Armstrong, Gregory T. ; Boop, Frederick A. ; Sanford, Robert A. ; Kun, Larry E. ; Merchant, Thomas E. ; Gajjar, Amar. / M1 Medulloblastoma : High risk at any age. In: Journal of Neuro-Oncology. 2008 ; Vol. 90, No. 3. pp. 351-355.
@article{42d3efd68447433282dc289baf487002,
title = "M1 Medulloblastoma: High risk at any age",
abstract = "Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defin ed. Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. Results: 55 patients were <3 years old and 230 patients were >3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). Conclusions : Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.",
keywords = "Cytology, Infant, Medulloblastoma, Metastatic, Prognosis, Survival",
author = "Sanders, {Robert P.} and Arzu Onar and Boyett, {James M.} and Alberto Broniscer and Morris, {E. Brannon} and Ibrahim Qaddoumi and Armstrong, {Gregory T.} and Boop, {Frederick A.} and Sanford, {Robert A.} and Kun, {Larry E.} and Merchant, {Thomas E.} and Amar Gajjar",
year = "2008",
month = "8",
day = "18",
doi = "10.1007/s11060-008-9671-9",
language = "English (US)",
volume = "90",
pages = "351--355",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - M1 Medulloblastoma

T2 - High risk at any age

AU - Sanders, Robert P.

AU - Onar, Arzu

AU - Boyett, James M.

AU - Broniscer, Alberto

AU - Morris, E. Brannon

AU - Qaddoumi, Ibrahim

AU - Armstrong, Gregory T.

AU - Boop, Frederick A.

AU - Sanford, Robert A.

AU - Kun, Larry E.

AU - Merchant, Thomas E.

AU - Gajjar, Amar

PY - 2008/8/18

Y1 - 2008/8/18

N2 - Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defin ed. Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. Results: 55 patients were <3 years old and 230 patients were >3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). Conclusions : Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.

AB - Background: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defin ed. Methods: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006. Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference. Results: 55 patients were <3 years old and 230 patients were >3 years old at diagnosis. We detected significant (P < 0.0001) associations between M1 disease and EFS for the entire cohort and for both younger and older patients. Among younger children, M1 patients had lower EFS than M0 (P = 0.0044). Conclusions : Children <3 years old with M1 medulloblastoma fared poorly in our small series. Survival for older children with M1 disease treated with higher-dose CSI was better than that of M2/M3 patients, but still less than optimal; our findings do not support reduction in therapy for either cohort.

KW - Cytology

KW - Infant

KW - Medulloblastoma

KW - Metastatic

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=56249092412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56249092412&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9671-9

DO - 10.1007/s11060-008-9671-9

M3 - Article

VL - 90

SP - 351

EP - 355

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -